Association of methacholine challenge test with diagnosis of chronic lung allograft dysfunction in lung transplant patients

2018 ◽  
Vol 32 (10) ◽  
pp. e13397 ◽  
Author(s):  
Atif S. Siddiqui ◽  
Gagan Kumar ◽  
Tilottama Majumdar ◽  
Edward A. Graviss ◽  
Duc T. Nguyen ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Challenge Test ◽  
Methacholine Challenge ◽  
Chronic Lung Allograft Dysfunction ◽  
Methacholine Challenge Test ◽  
Allograft Dysfunction ◽  
Transplant Patients

scholarly journals Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes

2021 ◽  
Vol 12 ◽  
pp. 204062232199344
Author(s):  
Filippo Patrucco ◽  
Elias Allara ◽  
Massimo Boffini ◽  
Mauro Rinaldi ◽  
Cristina Costa ◽  
...  
Keyword(s):  
Renal Function ◽  
Lung Function ◽  
Lung Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Forced Expiratory Volume ◽  
Chronic Lung Allograft Dysfunction ◽  
Allograft Dysfunction ◽  
Transplant Patients ◽  
Restrictive Allograft Syndrome ◽  
Trend Data

Background: Chronic lung allograft dysfunction (CLAD), a complication affecting the survival of lung transplanted patients, includes two clinical phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Everolimus is used in CLAD because of its antiproliferative mechanism. In lung transplant patients treated with everolimus, the clinical course of renal and lung function has not yet been assessed systematically in CLAD, BOS and RAS patients for more than 6 months. Methods: We retrospectively evaluated the 12-month follow-up of renal and lung function of lung-transplanted patients switched to everolimus and evaluated the reduction in immunosuppressant dosage (ISD) and mortality. Subgroups were based on indication for everolimus treatment: CLAD and non-CLAD patients, BOS and RAS among CLAD patients. Results: We included 26 patients, 17 with CLAD (10 BOS, seven RAS). After 1 year from the everolimus switch, we observed renal function improvement (serum creatinine −17%, estimated glomerular filtration rate +24%) and stable pulmonary function [forced expiratory volume in the first second (FEV1) −0.5%, forced vital capacity (FVC) +0.05%]. RAS patients had progressive functional loss, whereas BOS patients had FEV1 improvement and FVC stability. All-cause mortality was higher in the CLAD versus non-CLAD group (41% versus 11%), without differences between BOS and RAS patients ( p > 0.05). All patients had significant and persistent ISD reduction. Conclusion: Lung transplant patients treated with everolimus had improvements in renal function and reduced ISD. We observed sustained improvements in lung function for CLAD related to BOS subgroup results, whereas RAS confirmed the 1-year worsening functional trend. Data seem to suggest one more piece of the puzzle in CLAD phenotyping.

BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients

2017 ◽  
Vol 31 (3) ◽  
pp. e12898 ◽  
Author(s):  
Cristina Berastegui ◽  
Susana Gómez-Ollés ◽  
Sara Sánchez-Vidaurre ◽  
Mario Culebras ◽  
Victor Monforte ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Chronic Lung Allograft Dysfunction ◽  
Allograft Dysfunction ◽  
Transplant Patients

scholarly journals The Role of Galectins in Chronic Lung Allograft Dysfunction

Lung ◽  
2021 ◽  
Author(s):  
Miriana d’Alessandro ◽  
Laura Bergantini ◽  
Antonella Fossi ◽  
Elda De Vita ◽  
Felice Perillo ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Inverse Correlation ◽  
Bronchiolitis Obliterans Syndrome ◽  
Operating Characteristics ◽  
Blood Concentrations ◽  
Chronic Lung Allograft Dysfunction ◽  
Independent Variables ◽  
Allograft Dysfunction ◽  
Transplant Patients ◽  
Clinical Biomarkers

Abstract Background Galectins are proteins that bind β-galactosides such as N-acetyllactosamine present in N-linked and O-linked glycoproteins and that seem to be implicated in inflammatory and immune responses as well as fibrotic mechanisms. This preliminary study investigated serum galectins as clinical biomarkers in lung transplant patients with chronic lung allograft dysfunction (CLAD), phenotype bronchiolitis obliterans syndrome (BOS). Materials and Methods Nineteen lung transplant patients [median age (IQR), 55 (45–62) years; 53% males] were enrolled in the study. Peripheral blood concentrations of galectins-1, 3 and 9 were determined with commercial ELISA kits. Results Galectin-1 concentrations were higher in BOS than in stable LTX patients (p = 0.0394). In logistic regression analysis, testing BOS group as dependent variable with Gal-1 and 3 as independent variables, area under the receiver operating characteristics (AUROC) curve was 98.9% (NPV 90% and PPV 88.9%, p = 0.0003). With the stable LTX group as dependent variable and Gal-1, 3 and 9 as independent variables, AUROC was 92.6% (NPV 100% and PPV 90%, p = 0.0023). In stable patients were observed an inverse correlation of Gal-3 with DLCO% and KCO%, and between Gal-9 and KCO%. Conclusion Galectins-1, 3 and 9 are possible clinical biomarkers in lung transplant patients with diagnostic and prognostic meaning. These molecules may be directly implicated in the pathological mechanisms of BOS. The hypothesis that they could be new therapeutic targets in BOS patients is intriguing and also worth exploring.

CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival

2017 ◽  
Vol 94 ◽  
pp. 78-84 ◽  
Author(s):  
Sabine Dettmer ◽  
Hoen-oh Shin ◽  
Jens Vogel-Claussen ◽  
Max Westphal ◽  
Axel Haverich ◽  
...  
Keyword(s):  
Lung Transplant ◽  
Chronic Lung Allograft Dysfunction ◽  
Allograft Dysfunction ◽  
Transplant Patients
Sign in / Sign up

Export Citation Format

Share Document